BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16807462)

  • 1. Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy.
    Cartei G; Binato S; Sacco C; Bearz A; Scalone S; Ceravolo R; Cingarlini S; Fantoni U; Palamidese A; Iop A; Colombrino E
    Ann Oncol; 2006 May; 17 Suppl 5():v47-51. PubMed ID: 16807462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.
    Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF
    Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
    Jassem J; Krzakowski M; Roszkowski K; Ramlau R; Słomiński JM; Szczesna A; Krawczyk K; Mozejko-Pastewka B; Lis J; Miracki K
    Lung Cancer; 2002 Jan; 35(1):73-9. PubMed ID: 11750716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of gemcitabine in combination with cisplatin in a randomized study of untreated patients with advanced non-small-cell lung carcinoma].
    Mehić B; Zutić H; Dizdarević Z; Lomigorić J
    Med Arh; 2004; 58(1):11-3. PubMed ID: 15017896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
    Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
    Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
    Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study.
    De Pas T; Curigliano G; Veronesi G; Catalano G; Catania C; Jereczek-Fossa B; Orecchia R; Spaggiari L; de Braud F
    Bull Cancer; 2004 Sep; 91(9):E273-7. PubMed ID: 15582897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
    Soto Parra H; Cavina R; Latteri F; Sala A; Dambrosio M; Antonelli G; Morenghi E; Alloisio M; Ravasi G; Santoro A
    Ann Oncol; 2002 Jul; 13(7):1080-6. PubMed ID: 12176787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
    Crinò L; Scagliotti G; Marangolo M; Figoli F; Clerici M; De Marinis F; Salvati F; Cruciani G; Dogliotti L; Pucci F; Paccagnella A; Adamo V; Altavilla G; Incoronato P; Trippetti M; Mosconi AM; Santucci A; Sorbolini S; Oliva C; Tonato M
    J Clin Oncol; 1997 Jan; 15(1):297-303. PubMed ID: 8996156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer.
    Karacetin D; Incekara O
    J BUON; 2006; 11(2):181-4. PubMed ID: 17318968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.
    He J; Ying W; Yang H; Xu X; Shao W; Guan Y; Jiang M; Wu Y; Zhong B; Wang D; Tucker S; Zhong N
    Anticancer Drugs; 2009 Oct; 20(9):838-44. PubMed ID: 19668080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
    Cappuzzo F; Selvaggi G; Gregorc V; Mazzoni F; Betti M; Rita Migliorino M; Novello S; Maestri A; De Marinis F; Darwish S; De Angelis V; Nelli F; Bartolini S; Scagliotti GV; Tonato M; Crinò L
    Cancer; 2003 Jul; 98(1):128-34. PubMed ID: 12833465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
    Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M
    J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.